What new industry research reveals about the patient-centricity gap in clinical trials

Sonia Hunte — Moderator, Xtalks
Good day to everyone joining us, and welcome to today's Xtalks webinar. Today's talk is entitled "Beyond Good Intentions: What New Industry Research Reveals About the Patient Centricity Gap in Clinical Trials." My name is Sonia Hunte, and it's my pleasure to be your Xtalks moderator for today.

Sonia Hunte — Moderator, Xtalks
Today's webinar will run for approximately sixty minutes. It's a roundtable discussion with limited slides that share data from this new research. This presentation also includes a Q&A session with our speakers. The webinar is designed to be interactive, so please feel free to submit your questions and comments for our speakers throughout this presentation by using the questions chat box, located in the control panel on the right-hand side of your screen. If you require any assistance, please contact me using this chat panel. I'd also like to welcome our attendees viewing via LinkedIn Live — please submit your questions via the comments tab. All participants are in listen-only mode, and this event will be recorded and made available for streaming to those who have registered on xtalks.com.

Sonia Hunte — Moderator, Xtalks
I'd like to thank Suvoda, who developed the content for this presentation. Suvoda is a global clinical trial technology company that provides real-time solutions to help sponsors, CROs, sites, and patients navigate critical moments with confidence. Its technology has supported more than 6,000 clinical trials across 115 countries. With offices across the US, Europe, and Japan, Suvoda merged with Greenphire, expanding its capabilities in clinical trial financial management and patient support.

Sonia Hunte — Moderator, Xtalks
Now I'd like to welcome our speakers. First, Daniela Duffet, who leads Suvoda's global eClinical Solutions consulting team and is based in the Barcelona office. She works closely with clients and prospects delivering presentations and demonstrations while serving as a subject matter expert on Suvoda's solutions. Daniela joined Suvoda several years ago in the services delivery organization, where she worked in project management and gained deep hands-on experience in IRT solution delivery. This background enables her to bring strong practical insight and real-world expertise to every consulting engagement.

Sonia Hunte — Moderator, Xtalks
Next, Nisarg Shah, Vice President at Everest Group, where he leads the life sciences IT outsourcing and advisory offerings with a focus on the R&D software and services value chain. He advises global service providers, software providers, and pharmaceutical enterprises on digital transformation, product strategy, go-to-market strategy, mergers and acquisitions, competitor assessments, and vendor evaluations. He has authored industry reports on clinical development software categories and decentralized clinical trials, and regularly contributes thought leadership on technology trends shaping the life sciences industry.

Sonia Hunte — Moderator, Xtalks
And Elizabeth Smith, Director of Product Management at Suvoda, who leads the development of transformative solutions to streamline the clinical trial experience for patients, sites, and sponsors. She began her career as a clinician with direct experience in clinical trials, bringing firsthand knowledge of clinical research together with deep experience in product management and strategy. She is currently focused on delivering effective, user-centered solutions for participant payments, travel, and scheduling to meet evolving trial needs and set new standards for quality and value. With introductions complete, I'll now hand the controls to Daniela.

Daniela Duffet — Global eClinical Solutions Consulting, Suvoda
Thank you so much. We're really excited to have you all here today. We're going to be centering the discussion around findings from a new and exclusive Everest Group industry survey to examine the gap between patient centricity as a concept and patient centricity as a reality. For those joining us, we'll be sharing the full white paper for download, so you'll get early access. Our goal today is not to convince you that patient centricity matters, but to dig into where we are as an industry on that journey — where we're falling short, what differentiates organizations making measurable progress, and what concrete steps sponsors can take to move from patient centricity intent to actual delivery. So let's dive in.

Daniela Duffet — Global eClinical Solutions Consulting, Suvoda
Before we get into specific findings, Nisarg, I'd love it if you could share an overview of the Everest Group industry survey. What was the inquiry you were investigating? Who did you survey? And why did you think this topic was important to examine?

Nisarg Shah — VP, Everest Group
We set out to explore two or three key exam questions. One: does patient centricity still matter today? Spoiler alert — it does. But we still had to investigate it. We also wanted to understand both the sponsor/CRO and site perspectives: where does the journey still break down? We've been making more investments in patient-centric trial execution, but there are still gaps that need to be addressed. And ultimately, what can the industry do to solve for those gaps?

Nisarg Shah — VP, Everest Group
We surveyed 103 respondents across large pharma, mid-sized pharma, CROs, and sites — each with previous exposure to running clinical trials. We also looked at different geographies to understand nuances across regions: North America, UK, Europe, China, Japan, and Australia. So this was a well-rounded survey across various stakeholder and geographic categories to unpack what the industry really thinks about patient-centric clinical trial execution.

Daniela Duffet — Global eClinical Solutions Consulting, Suvoda
Thank you. It's really critical for our audience to have a snapshot of how global and varied the respondents were. Now, before we dive into specific numbers, Elizabeth — can you share why Suvoda got involved and what role Suvoda played?

Elizabeth Smith — Director, Product Management, Suvoda
Suvoda partnered with Everest Group in this research because the question it's asking is one we're working on every day: why hasn't patient-centric intention translated into patient-centric delivery? We've brought together our eConsent, eCOA, scheduling, travel, and payments capabilities into a single platform, with a vision to enable a unified patient journey. In that context, we constantly hear about fragmentation from the sponsors and sites we work with. We wanted independent, third-party data on whether that fragmentation is systemic — and it is. It's also a problem all of us can relate to. Most of us have experienced medical interactions where things feel scattered, where we have to interact with multiple different systems. It's confusing and frustrating, and our participants are experiencing that to an exponential degree.

Daniela Duffet — Global eClinical Solutions Consulting, Suvoda
That makes complete sense. One overarching theme of the data is that although the need for patient centricity isn't new, sponsors, CROs, and sites all agree that it's intensifying. Nisarg, what does the research tell us is driving that, and why now?

Nisarg Shah — VP, Everest Group
The data reveals that the need for patient-centric clinical trial execution is intensifying — 85% of our respondents said its importance has increased in the past two to three years. We identified four key industry forces pushing this forward. First, the bar for data quality is intensifying — pharma sponsors need better clinical trial data for submissions, and CROs and sites are looking at better data quality as a path to increased trial success. Second, competitive intensity is also increasing: pharma is competing to bring drugs to market as fast as possible, CROs operate in a cutthroat environment, and sites want to stay relevant and demonstrate the ability to participate in future trials. Third, protocols are getting more complex as pharma sponsors move into new therapy areas like rare disease and oncology, passing additional burden to sites and patients around data submission frequency. And fourth, regulatory expectations are becoming more explicit and stricter about how patients participate in clinical trials.

Nisarg Shah — VP, Everest Group
At the same time, the industry has already made progress. Consumer-grade technology is making its way into clinical trials, with many providers designing for the patient and by the patient. Remote participation models have raised the bar for how patients engage with trials from home. And site enablement tools have become more sophisticated, supporting reimbursement, scheduling, visit tracking, and more effective patient engagement. So to summarize: the need for patient centricity is higher than ever, but the industry also has some of the tools to support it.

Daniela Duffet — Global eClinical Solutions Consulting, Suvoda
And it's interesting to hear how different stakeholders view it differently, but the overarching response is the same — it's important, the importance is increasing, and the execution is achievable. Elizabeth, does what Nisarg described match the pressures you're seeing from sponsors day to day — and what happens when the industry doesn't pay attention to these patient-centric needs?

Elizabeth Smith — Director, Product Management, Suvoda
This absolutely matches what we're seeing. We've seen it accelerating even more in the last twelve months. We've reached a point where every major customer conversation is touching on patient experience — it's not a nice-to-have, it's an essential requirement. Especially in rare disease trials, there's competition for participants. The trial with the best patient experience is the one a patient will join and stick with.

Elizabeth Smith — Director, Product Management, Suvoda
But if we don't get it right, the opposite is true. Patients drop out. The cost of losing participants compounds for sponsors — they have to spend on recruitment to replace them, there's a cost to interruption of the data, and there are expensive timeline delays. Ultimately, all of this delay is getting new treatments to market, which is costly for everyone. Even worse, when we provide a bad patient experience, we lose patient trust. A patient who has a bad experience is less likely to ever participate again. The stakes are truly very high.

Daniela Duffet — Global eClinical Solutions Consulting, Suvoda
The risk of not getting it right is very real. Some of the data in the survey reveals how sponsors and sites view the different impacts, and I found that quite interesting. Nisarg, could you walk us through the perception gap between different stakeholders in more detail?

Nisarg Shah — VP, Everest Group
It's less a disagreement than differences in visibility. Sponsors usually see patterns across studies, whereas sites see complexity accumulating for individual patients in day-to-day delivery. According to sites, patients experience friction because of excessive visits and logistics, technical issues with applications they're using, multiple sign-ins, and fragmented handoffs across the journey. Whereas sponsors tend to attribute friction to inconsistency in the site experience. So they're viewing the end outcome through different lenses.

Nisarg Shah — VP, Everest Group
What we have to acknowledge is that it's ultimately the site stakeholders who absorb a lot of the complexity that sponsors may not fully see. In our survey, a site on average uses approximately 22 sponsor-mandated systems within a single study — across eCOA, ePRO, and many other solutions. If they're all disjointed, it exacerbates the situation significantly. 71% of sites identified integration as one of the major barriers to patient-centric trial execution success. And in most situations, sites adopt the systems sponsors mandate — they may not have a say in which systems they'd prefer to use. That eventually translates into additional workload for sites, and the industry is left wondering why patients are dropping out or why data quality is being impacted.

Daniela Duffet — Global eClinical Solutions Consulting, Suvoda
To summarize: sponsors are focusing on patterns across their portfolios, but sites are absorbing complexities at the individual study level that sponsors may not be aware of. I visited a clinical research site two weeks ago, and this lines up perfectly with what they told me. They showed me the cheat sheets they create for themselves for every study — and if we're talking about 22 systems per study, multiply that by however many studies they're running simultaneously. The onboarding for each platform is a huge struggle. Thank you, Nisarg.

Daniela Duffet — Global eClinical Solutions Consulting, Suvoda
We can't lose sight of the patient's voice. Elizabeth, whose read do you think is closer to what patients actually experience — sponsors or sites?

Elizabeth Smith — Director, Product Management, Suvoda
Based on the many conversations I've had with sponsors, sites, and patients, I think the sites' read is closer. It really makes sense — they're closest to the patient and experiencing most of the journey with them. We see that reflected in the data: 34% of sponsors flagged excessive visits and logistics as friction points, versus 82% of sites. What we're really talking about is constant context switching. 22 systems — every system a coordinator logs into is mental overhead. There's time spent reconciling all those systems, and all that time is spent not with patients. When we talk to sites about pain points, they never say "I need a new tool." They say "I need to not have so many tools."

Elizabeth Smith — Director, Product Management, Suvoda
That same pain is experienced by participants. I had one participant conversation that sticks out in my mind. He talked me through his trial experience, and you could feel the frustration coming through. He described using one app for surveys, another for payments, getting phone calls for scheduling, email documents for consent, and still having to deal with paper forms — all for one single, fairly simple study. As an industry, we say we've digitized the journey, and technically that's true — most of those things are digital. But they're not connected. So the journey is still painful. We're giving patients and sites technology overload.

Daniela Duffet — Global eClinical Solutions Consulting, Suvoda
My biggest takeaway from what you're saying is that we need to listen to sites more — they're the bridge that closes that gap. Now I want to jump to another encouraging finding from the research: organizations that have deployed patient-centric solutions are more optimistic about improving their clinical trial KPIs than those that have not. Nisarg, for organizations that have already deployed some of these solutions, what are they actually reporting?

Nisarg Shah — VP, Everest Group
This is a classic case of: you'll only know the value once you've tried it. The delta between non-adopters and adopters of unified patient experience platforms reveals a significant gap in terms of expected versus actual value realized. The KPIs that bubbled up are the ones mission-critical for business users: lower cost per patient enrolled, faster completion time, improved patient satisfaction and experience, better adherence, fewer dropouts, and better data accuracy and completeness. The results are encouraging because a unified patient-centric platform solves for some of the frictions we've been discussing — fewer systems to integrate, fewer data silos, a simplified user experience for sponsors, CROs, and sites alike.

Nisarg Shah — VP, Everest Group
The key message isn't that you need to go all out and unify your platform immediately. The core message is that you need a strategy that integrates some of your capabilities into a single experience layer — and that's probably the one change that will really work wonders for this industry.

Daniela Duffet — Global eClinical Solutions Consulting, Suvoda
The deltas are huge between adopters and non-adopters across five major KPIs that anyone would want to improve. Elizabeth, does this match what you're hearing from customers who've made the shift?

Elizabeth Smith — Director, Product Management, Suvoda
It absolutely matches, and we're seeing the emotion that goes with it. Once these teams have experienced a connected journey, they don't even want to think about going back to the old way. Participants have a very similar reaction — they're used to having streamlined experiences in their regular lives, with consumer-grade apps for everything they do. When they have a unified experience in a trial, it meets that expectation. It's easier for them to do what they need to do, and they're more likely to actually do it. That contributes to better adherence and better retention.

Elizabeth Smith — Director, Product Management, Suvoda
Some of these things serve both goals at the same time. For example, self-service registration in the app — the participant gets control over their own information, but it also removes data entry burden and reduces errors from site staff. Or a micropayment: the patient completes a questionnaire, and a stipend payment is automatically triggered. The site user doesn't have to do anything. The patient gets rewarded, no extra work for the site. Patient centricity and site centricity aren't competing with each other. If we do them right, the same features help us achieve both.

Nisarg Shah — VP, Everest Group
Elizabeth, your point reminded me of something a site shared with me a few months ago. They described it as a "Monday morning effect." Site users also have regular lives — they're used to the Instagrams and Facebooks of the world, which promise a great UX and smooth experience. And then suddenly they have to log into an eCOA environment, and all of that goes out the window in terms of the number of logins, the training required to get up to speed on a new study. There is a real deficit gap between the experiences we're used to in our daily lives versus what clinical ops environments offer. The industry won't overhaul entirely to match consumer platforms, but there is definitely a welcome change if things are made much smoother to navigate.

Daniela Duffet — Global eClinical Solutions Consulting, Suvoda
That Monday morning effect is very jarring. And we keep echoing the same themes — the importance of listening to sites, making sure patients' needs are considered through sites, because we can't do patient centricity without site centricity. That's a perfect bridge to our next topic: solutions. The white paper lays out a playbook of steps sponsors and CROs can take to enable patient centricity in practice. Nisarg, could you share some of those steps?

Nisarg Shah — VP, Everest Group
If I were to break down the playbook into three key takeaways, they would be: connect the data and technology layers; redesign processes around the patient journey; and align people and governance around shared outcomes. On data and technology: sponsors need to select interoperable solutions that establish a unified view of the patient journey. I'm not saying you need an end-to-end patient-facing platform immediately — that may be a good north star, but not everyone has the capabilities to go all in right now. It's about integrated solutions coming together for the unified patient journey. For CROs, it's about coordinating system integration as the bridge between sponsors and sites. For sites, it's about validating usability, flagging technological issues upfront, and working in unison with sponsors and CROs to solve them.

Nisarg Shah — VP, Everest Group
On process: sponsors, CROs, and sites need to capture the voice of the patient during the protocol design stage itself — start from the very beginning. If you think about what a protocol means for the patient only after it's been designed, you're setting yourself up for challenges downstream. For CROs, it's about standardizing communications across the trifecta. For sites, it's not about saying yes to everything, but about assessing feasibility and pushing back where appropriate. On people and governance: there's often friction between what sponsors see, what CROs see, and what sites see. A common RACI framework can help clarify who owns what and how to solve for it together — aligning everyone toward a common shared goal and providing structured patient insight feedback during startup, evaluation, and execution phases.

Daniela Duffet — Global eClinical Solutions Consulting, Suvoda
That's a really valuable, practical framework. And it's a great way to lay out that different stakeholders need to own different parts of this across technology, process, and governance. Elizabeth, from your platform perspective, which of those items do you see making the biggest difference?

Elizabeth Smith — Director, Product Management, Suvoda
I'd flag two as highest priority. First, capturing the site and patient voices in a structured way. Our research has informed so many of the things we've built, but it really changed what we were designing. Sites told us they wanted control over scheduling, but they also wanted patients to have agency — so we built both. You can't design a patient-centric experience in a vacuum, just as you can't design a patient-centric trial from a conference room. We need that information directly from the people impacted.

Elizabeth Smith — Director, Product Management, Suvoda
Second, having a core system with a unified data layer — and this is critical both now and as we look forward to AI. Connecting those systems isn't just providing convenience. It also gives us the ability to make proactive interventions. When milestones, tasks, and payments are all in one layer, a missed visit or a stalled reimbursement surfaces in time to act on it rather than showing up in a retention report three months later after we've already lost the participant. It's not a capability problem — we have all the tools we need. It's a coordination problem. We just need to orchestrate and connect the things we've already built.

Daniela Duffet — Global eClinical Solutions Consulting, Suvoda
Orchestrating what we already have. And that brings me to technology fragmentation specifically. What did industry respondents say technology vendors can do to make a positive difference?

Nisarg Shah — VP, Everest Group
We asked respondents to rate how much they value certain capabilities from a software provider, and it's difficult to cherry-pick one because all five dimensions look very important. Of course, technology providers focus on the technological aspects — delivering a unified patient experience, strong UX, interoperability, and scalability as studies move from phase one to phase three. Those are table stakes. But some of the other parameters don't point to technological muscle so much as an orchestrator and partner muscle. Respondents want vendors to act as strategic partners — not just someone who shows up for an RFP and offers support when a query comes in, but someone who's at the decision-making table, helping clients figure out what they need to address their challenges, sharing best practices and use cases from peers.

Nisarg Shah — VP, Everest Group
A great technology provider also proactively engages patients throughout the clinical trial journey — not just through solution features, but by listening to the voice of patients and incorporating their feedback into the solution design roadmap. My key message to buyers is: don't just think of your technology partners as technology partners. Ask them for more. Ask for use cases, success stories, and how clients and software providers can work in unison to alleviate the problems that have been age-old for a while.

Daniela Duffet — Global eClinical Solutions Consulting, Suvoda
The response rates on those dimensions are remarkably high — it's a very clear picture of the direction the industry needs to head. Elizabeth, what needs to happen for the industry to close the gap on patient centricity?

Elizabeth Smith — Director, Product Management, Suvoda
Study teams and their partners do best when we break down silos and focus on the patient experience throughout the entire trial — not just at kickoff, but across the whole trial lifespan. And accountability is essential for that. There's a bit of a bystander syndrome. When I was an EMT, we'd always tell people that in an emergency, you need to point at one specific person and say "you — call 911," because if you don't, everyone assumes someone else is doing it and no one calls. Patient centricity in our industry right now has that same dynamic — it's everyone's responsibility, so it becomes no one's particular responsibility. Where we're seeing success is in organizations that have a point person who owns retention and engagement outcomes, with the ability to make decisions and act.

Elizabeth Smith — Director, Product Management, Suvoda
And when organizations do those things, they have high expectations — rightly so. That finding that 92% of respondents want a strategic partner, not just a software provider, matches exactly what we're hearing. Our customers don't want us to just give them a website. They want implementation guidance, industry expertise, and a roadmap they get to shape with their feedback to keep improving their tools — because they know what they need.

Daniela Duffet — Global eClinical Solutions Consulting, Suvoda
Assigning ownership makes complete sense as a tangible way to ensure those benefits are realized. For my last question, I'd like to look forward: where do you each see patient centricity heading in the next two to three years? Elizabeth, would you like to start?

Elizabeth Smith — Director, Product Management, Suvoda
The direction I see us going is shifting from reactive to proactive. Right now we're trying to catch patients when they're struggling, retain them as they're dropping out. But ideally, three years from now, with all these connected processes and connected tools, we can make more informed decisions and pay extra attention to participants right when they start to struggle. We'll notice when they're slow to schedule appointments or get real-time feedback when they're unhappy. Trial staff will be able to quickly direct their attention to the patients who need it most.

Elizabeth Smith — Director, Product Management, Suvoda
And yes — it will be powered and accelerated by AI, which will help flag engagement risks early, cut down administrative work for sites, and help teams interpret connected data. But that only works when everything is connected. We can't layer AI on fragmented data because then we'll just get shinier fragmentation — it would still be broken. From a patient perspective, the winners won't be the ones who digitize more of the journey. As I mentioned with that participant's story, we already have enough digital things. The winners will be the ones who can connect those things and make the journey feel less fragmented — more human. Success will look like a patient who has an easy experience and barely notices the technology they're using at all.

Nisarg Shah — VP, Everest Group
I want to point out that this is one of the few webinars where we managed to not bring in AI until the forty-five minute mark. But I do agree — the future of patient centricity will be accelerated primarily by connectedness and more interoperability, with AI as an enabler if done right. There are a lot of shiny pilots out there, and what the industry is really asking is: how does this help me become more efficient or elevate my existing role? That's the core problem statement everyone is trying to figure out.

Nisarg Shah — VP, Everest Group
It's also a situation where pharma, CROs, and sites need to figure out the right suite of ecosystem solutions to deploy versus having disparate point solutions and data silos. If you want to deploy AI on data silos, it's like trying to drive a Ferrari on a pothole road — it just won't work. I see more acceleration toward this becoming a boardroom-level topic in the next few quarters.

Daniela Duffet — Global eClinical Solutions Consulting, Suvoda
Exciting times ahead — a lot to implement and work on, but the industry is headed in the right direction. Thank you both for the incredible input. Let's now open it up to audience Q&A.

Q&A — Audience Question
Do you see usability improving over time? It's one thing for software to be connected on a platform, but if those of us who use these systems don't find them easy to use or easy to learn, it doesn't solve the problem.

Elizabeth Smith — Director, Product Management, Suvoda
The expectation that clinical tech matches consumer tech is the direction we need to go, and user experience will continue evolving and getting better across the industry. We have a whole team of product designers working on this right now. We incorporate user experience into designs from the very beginning — it can't be an afterthought. We're thinking about the whole platform from the start: not how does eCOA work, how does scheduling work — but how do these things work together to make the user experience easy for everyone. That means cutting down and simplifying wherever we can: one login, one place to enter data, eliminating manual and duplicate steps. And we get feedback throughout the process — from a rough sketch of a mockup to a first prototype. Getting feedback on usability early and often is what drives the experience in the consumer-friendly direction it needs to go.

Nisarg Shah — VP, Everest Group
We also looked at usability in our survey — it's one of the most important metrics sponsors, CROs, and sites use to measure patient-centric software, but it's also one where satisfaction is currently low. There's a lot of delta to be covered, primarily because of what we've been discussing: too many handoffs, user experiences that are too cluttered — not easy to use and not easy to learn. That's where the ecosystem needs to improve in terms of solution design and communicating capabilities in a way that sponsors, sites, and CROs can easily comprehend and use.

Q&A — Audience Question
How much would hybrid and remote trials push the introduction of integrated solutions and help ease the workload of sites?

Elizabeth Smith — Director, Product Management, Suvoda
We've already seen a precedent established here. We went hard and fast in the hybrid direction during COVID, and it forced us to adapt and adopt a lot of new things. There are still trials where it hasn't been practical or where it's been resisted, but the more we expand digital and hybrid trials, the more we can increase our footprint, get more people into the trial, and make things easier for sites. If participants aren't physically on-site handing over papers, sites can't be expected to handle manual data entry — they're going to figure out a smoother, better way to support that process. The more these models are adopted, the easier things will become.

Nisarg Shah — VP, Everest Group
It has the potential to be easier, but there are challenges. COVID led to almost everyone positioning themselves as DCT or hybrid clinical trial providers. Some did not live up to the expectations, and the industry has since stabilized — but we still hear of sites trying to make the business case for deploying such solutions in phase one and phase two trials. And there are still many point solutions out there for eCOA, eConsent, televisits, wearables, and more. If you're thinking about it from a point-solution strategy, you'll likely end up back at square one with the same challenges we've been discussing. It has potential if you're thinking about the broader principles: interconnected ecosystems, processes centered around patients, and governance where everyone is acting toward a single shared goal.

Q&A — Audience Question
Could you say a little more about how you see AI factoring into the patient centricity conversation?

Nisarg Shah — VP, Everest Group
Sponsors still see AI as high risk when it touches the patient directly — that conversation is probably a few years out. But where AI can make an impact now is in operational metrics: how to design a clinical trial in a better format, how to surface predictive insights for sponsors and CROs, and how to accelerate clinical trials by automating laborious work that site and CRO staff often get pulled into. Anything that touches the patient directly is seen as high risk. But anything internal — generative AI, agentic AI, foundational LLMs — is very much in the realm of possibility and where we're seeing a lot of innovation.

Elizabeth Smith — Director, Product Management, Suvoda
I'd add the angle of patient safety. Patient safety starts with protecting patient data, and as we incorporate AI, we've been thinking carefully about how to do it in the most safe and effective way. The answer is that it follows all the same guardrails as the rest of the platform — role-based access, study boundaries, auditability. Human oversight is always involved for any consequential decisions. This unified patient journey isn't just about connecting workflows — it's about connecting them responsibly so people see the right information at the right time, and study teams have the ability to act earlier without compromising any privacy or control for our patients.